Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease

The Food and Drug Administration approved the first direct oral anticoagulant nearly a decade ago. Since then, antithrombotic therapy has evolved swiftly, with research systematically addressing the use of these agents for the treatment of common medical conditions, such as atrial fibrillation. Of particular concern in recent years has been the question of how to manage atrial fibrillation and coronary artery disease when they occur together in the same patient. Yasuda and colleagues(1) now report in the Journal the results of the AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) trial. This multicenter, . . .